We engineered and employed a chaperone-like amyloid-binding protein Nucleobindin 1 (NUCB1) to stabilize human islet amyloid polypeptide (hIAPP) protofibrils for use as immunogen in mice. We obtained multiple monoclonal antibody (mAb) clones that were reactive against hIAPP protofibrils. A secondary screen was carried out to identify clones that cross-reacted with amyloid beta-peptide (Aβ42) protofibrils, but not with Aβ40 monomers. These mAbs were further characterized in several in vitro assays, in immunohistological studies of a mouse model of Alzheimer's disease (AD) and in AD patient brain tissue. We show that mAbs obtained by immunizing mice with the NUCB1-hIAPP complex cross-react with Aβ42, specifically targeting protofibrils and inhibiting their further aggregation. In line with conformation-specific binding, the mAbs appear to react with an intracellular antigen in diseased tissue, but not with amyloid plaques. We hypothesize that the mAbs we describe here recognize a secondary or quaternary structural epitope that is common to multiple amyloid protofibrils. In summary, we report a method to create mAbs that are conformation-sensitive and sequence-independent and can target more than one type of protofibril species.
| INTRODUCTION
Aggregation of proteins or peptides into amyloid fibrils is a characteristic pathological feature observed in many different diseases including type 2 diabetes mellitus (T2DM), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). [1] [2] [3] Amyloid aggregates present in the brain are associated with a reduction in the efficiency of coordinated synaptic transmission, loss of synaptic plasticity and contribute to cognitive impairment 4, 5 in AD [6] [7] [8] and other so-called tauopathies, 9 ,10 PD, 11 HD 12 and frontotemporal lobar degeneration (frontotemporal dementia, clinical amyotrophic lateral sclerosis and motor neuron disease). 13, 14 Misfolded protein aggregates outside of the central nervous system result in amyloidosis syndromes, such as light-chain amyloidosis, familial amyloid cardiomyopathy, familial amyloid polyneuropathy 15 and T2DM. 16 Amyloid proteins or peptides polymerize to form a cross-β sheet structure and progressively self-aggregate into soluble protofibrils, insoluble fibrils and eventually deposit as amyloid plaques in tissue. 17 However, normally folded species of these proteins or peptides have important biological functions, the amyloid fibrils and their prefibrillar aggregates exhibit toxicity. 18, 19 Antibodies that lead to clearance of the toxic forms of amyloid are likely more useful than those that target the monomeric amyloidogenic species. In fact, accumulating evidence suggests that prevention of aggregation of pathogenic amyloid species would prevent disease progression. 20 Clinical applications of antibodies that target amyloid conformations are primarily limited to AD. Passive immunization with monoclonal antibodies (mAbs) directed at amyloid beta-peptide (Aβ42)
aggregates has shown interesting preliminary results. 21 BAN2401
(BioArtic Neuroscience AB, Eisai Co., Ltd., currently in phase II) was obtained by immunizing mice with Aβ42 (E22G) protofibrils and recognizes early aggregates with low affinity for fibrils or monomers. 22, 23 Crenezumab (Genentech, Inc, currently in phase III) binds the middle domain and shows similar binding for Aβ42 monomeric, oligomeric and fibrillar species. 24 Finally, produced through a "reverse translational medicine" approach, aducanumab (Biogen, Inc, currently in phase III) was isolated from B-cells of healthy advancedage donors, who are hypothesized to harbour naturally developed antibodies against Aβ. Aducanumab selectively targets aggregates and dose-dependently reduces amyloid deposition. 25, 26 We recently described a platform technology based on the use of the chaperone-like amyloid-binding protein (CLABP) NUCB1 to "cap," detoxify, and stabilize soluble intermediate protofibrils originating from various amyloidogenic proteins, such as Aβ42, α-synuclein, transthyretin and the human islet amyloid polypeptide (hIAPP). 27 Based on the hypothesis that there are common core protofibril conformations we tested the possibility that our technology could be used to develop antibody tools to detect these similarities. Here, we demonstrate that NUCB1-capped hIAPP protofibrils can be used as immunogen to produce mAbs against protofibrils derived from a different amyloid protein, Aβ42. We show that NUCB1-capped amyloid could serve as a platform technology for the discovery of therapeutic antibodies that bind elements unique to structured amyloid intermediates.
| MATERIALS AND METHODS

| Peptide preparation
The hIAPP (Phoenix Pharmaceutics) was solubilized in HFIP at 1 µg/ µl, dried and stored at −80°C. On the day of the experiment, hIAPP was solubilized in 20 mmol/L sodium phosphate buffer, pH 7.6 to a final concentration of 10 µmol/L, incubated at 25°C and tested at different time points. Aβ40 or Aβ42 (American Peptide) synthetic peptide was solubilized in HFIP at 1 µg/µl, dried and stored at −80°C. On the day of the experiment, Aβ42 was reconstituted in 2 mmol/L NaOH to 1 µg/µl, dried and diluted in 20 mmol/L sodium phosphate buffer, pH 8.0 to a final concentration of 10 µmol/L. The peptide was incubated at 37°C and tested at different time points.
The Ca 2+ -free sNUCB1 mutant (mtNUCB1) was engineered as previously described. 
| Immunogen preparation and immunization strategy
The mtNUCB1-capped hIAPP complex was prepared by co-incubating mtNUCB1 (10 µmol/L) and hIAPP (33 µmol/L) peptide at 37°C for 3 hours while stirred. The capped-protofibril containing solution was then applied to a Superdex200 26/60 PG size exclusion chromatography (SEC) column (GE Healthcare, Piscataway, NJ) equilibrated with buffer (20 mmol/L sodium phosphate, pH 7.6, 150 mmol/L NaCl). The main peak was collected, characterized 27 and used as immunogen. ImmunoMax mice (n = 3) were immunized with consecutive boosts of NUCB1-hIAPP complex and produced robust titer to the immunogen.
| Dot blot
The recombinant hIAPP peptide was incubated at the monomeric con- at RT. The membrane was incubated with our mAbs (4A8.E11, 4B1.H9, 3F2.E10, 5C9.A2, 1:100), the anti-Amylin (hIAPP) antibody (Abcam, 1:1000) and the polyclonal anti-oligomer A11 antibody (ThermoFisher Scientific 1:1000) diluted in TBS for 1 hour at RT followed by three washes with TBS-T (TBS and 0.05% Tween-20). The membranes were then incubated with horseradish-peroxidase-conjugated anti-rabbit secondary antibody (1:10 000) in TBS for 30 minutes at RT followed by two washes with TBS-T and a subsequent wash with TBS.
The blots were developed using the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific). 
| Antibody production and purification
The hybridoma lines were cultured in Hi-Growth Hybridoma Media and stored in 1x DPBS, 10% glycerol, 0.02% NaN3. All mAbs were purified by SEC to remove protein aggregates and immediately used for the assays, in order to avoid potential artefacts due to avidity effect.
| Fluorescence correlation spectroscopy
Fluorescence correlation spectroscopy (FCS) was performed using the ConfoCor 2 system (Carl Zeiss, Jena, Germany) consisting of an Temporal autocorrelation curves were fitted using the theoretically derived autocorrelation function for a system that consists of a single molecular species with one triplet state when the molecules are undergoing free three-dimensional (3D) diffusion: 
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To allow direct graphical comparison of characteristic decay times, the temporal autocorrelation curves were normalized to the same amplitude, G n (τ) = 1 at = 10 µs.
| Surface plasmon resonance
Surface plasmon resonance (SPR) studies were carried out with the ProteOn XPR36 protein interaction array system (Bio-Rad) based on SPR technology.
The antibodies were immobilized in the vertical direction on GLM sensor chips (Bio-Rad) using amine-coupling chemistry, as described previously, 29 followed by a blocking step with ethanola- | 2105
performed at 25°C and the data were normalized by interspot and by buffer. 
| Thioflavin-T binding assay
| RESULTS
| Immunization campaign and hybridoma screen for the discovery of tractable mAbs
The engineered Ca 2+ -free NUCB1 inhibits hIAPP aggregation (Figure 1A ) by binding to and stabilizing short protofibrils ( Figure S1 ), as previously reported. 27 The hIAPP-NUCB1 complex was purified using SEC ( Figure 1B) , characterized by atomic force microscopy (AFM) and ELISA ( Figure S1 ) and injected into three mice that showed robust titre to the immunogen ( Figure S2A ). The immunization campaign ( Figure 1C ) resulted in 752 screened fusion wells that were subjected to a pre-subclone screen by ELISA for their reactivity to the immunogen complex NUCB1-hIAPP as well as to NUCB1 (Figure S2B Figure 1D ).
| Screening of conformation-sensitive, sequence-independent mAbs
To test our hypothesis that NUCB1-hIAPP originated mAbs would detect the common quaternary amyloid protofibril structure independently from the primary sequence, we analysed whether they cross-react with structured protofibrils originating from the Aβ42 peptide.
Sandwich ELISA and FCS were used to determine whether mAbs bind Aβ monomers or protofibrils. Sandwich ELISA shows that each mAb specifically binds to the protofibril enriched pools of Aβ42 antigen and not to Aβ40 monomers (Figure 2A-D, left column) . These data suggest that the conformation-sensitive anti-hIAPP mAbs specifically recognize the protofibril conformation in a sequence-independent way. 
where Ligand is the antibody and Analyte is the amyloid Notably, the minimal decrease in fluorescence exerted by the negative control is a commonly reported effect of the protein mass, also observed when hIAPP aggregates in the presence of BSA (Figure 1 ).
When the data were plotted together, it appeared that the antibodies have a comparable inhibitory effect on the two amyloid proteins ( Figure 3I-L) , except for 3F2.E10 that acts more potently on Aβ42 aggregation ( Figure 3K ). We hypothesized that the sequence-independent inhibition of amyloid aggregation may occur through functional binding of the antibodies to early pre-fibrillar aggregates, preventing them from maturing to the fibril state.
| Protofibril staining in APP 102 /TTA brain tissue
To test the ability of these mAbs to detect protofibrils in tissue, we tested target engagement in ex vivo tissue from a transgenic mouse model of AD. The cortex of APP 102 /TTA mice was sectioned and costained with polyclonal anti-Aβ antibody, our mAbs (4A8.E11, 4B1.H9, 3F2.E10, and 5C9.A2), as well as the lysosome membrane marker LAMP2 and the nuclear marker DAPI (Figure 4) . We observed that the mAbs staining was present in proximity, but not inside of the Aβ plaques stained by the total anti-Aβ antibody in the transgenic mice (Figure 4 ), but not in wild-type (WT) tissue or regions with no plaques (not shown). Furthermore, we observed co-localization of the mAbs staining with LAMP2 as well as DAPI (Figure 4 ). This staining pattern suggests that our mAbs do not bind to the Aβ species that deposit in plaques but only to intracellular species localized in the lysosome.
| Intraneuronal staining in human AD frontal cortex
Frontal cortex brain tissue obtained from a familial AD patient was serially sectioned and adjacent slices were stained with the positive control anti-Aβ42 antibody or our conformation-sensitive mAbs to test the signal localization using immunohistochemistry. We observed that while the anti-Aβ42 antibody stained both plaques and pyramidal neurons in the AD frontal cortex, none of our mAbs detected plaques, but specifically and strongly stained pyramidal cells ( Figure 5 ). These results suggest that the pyramidal neurons contain Aβ protofibril morphotypes, whereas the Aβ-dense plaques do not contain these structures, therefore strengthening the results obtained in animal tissue and confirming the conformation-sensitive feature of our mAbs.
| DISCUSSION
In the past decades, the pathologic role of toxic protofibrils in the development of amyloid diseases has been increasingly recognized, 32, 33 leading to the study of therapeutics targeting early amyloid species to prevent large aggregates and plaque formation. Aside from the biologics currently in clinical trials, the polyclonal antibody A11, described more than 10 years ago, has been a useful tool for researchers for detecting the oligomeric species of amyloid.
This polyclonal antibody was produced using the C-terminal thioester Aβ40 monomers tethered to gold colloid nanoparticles as an immunogen. 18 Alternatively, the monoclonal WO1 and WO2 antibodies were created using sonicated fibrils and react to the general structure of fibrils from many amyloid sources. 34 The murine version of BAN2401, mAb158, was produced using protofibrils obtained from a mutated Aβ42 peptide (E22G, Arctic mutation). 35 Clone 13C3
was created using Aβ42 fibrils followed by screening for protofibril reactivity. 36 Recently, an anti-Aβ42 polyclonal antibody has been obtained by immunizing animals with isolated Aβ42 protofibrils. 37 In contrast to these approaches, we have created a platform technology using the novel NUCB1-capping method to produce stable amyloid protofibrils 27, 34 that can be used as immunogen to create panels of conformation-sensitive mAbs. We hypothesized that our technology could be used to produce conformation-sensitive, sequence-independent mAbs that detect the quaternary structure of the protofibrils and bind to early amyloid aggregates independently from the primary structure.
In this work we show that immunizing animals with hIAPP protofibrils stabilized by the CLABP, NUCB1, can produce mAbs that bind both hIAPP and Aβ protofibrils and we describe the methodology used to screen for mAbs with this conformation-sensitive We further studied these mAbs using human familial AD frontal cortex samples. The AD tissue displayed Aβ-positive plaques and Aβ-positive intraneuronal staining pattern. Using serial sections and imaging near the same area, we found that our mAbs do not display a plaque-like pattern, but rather showed a specific intracellular pyramidal neuron staining. These data support the mouse tissue staining pattern and therefore we conclude that our mAbs do not react with Aβ-positive plaque, but specifically bind to an intraneuronal protofibril conformation.
In summary, this work shows that our platform technology of NUCB1-capped hIAPP protofibrils is a suitable tool for discovering mAbs with different reactivity profiles. We provide a detailed screening platform to assess functional binding and target engagement in in vitro and ex vivo models. These anti-protofibril antibodies 
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